Target intelligence / Profile preview

Salmonella enterica serovar Typhi Vi capsular polysaccharide (Vi polysaccharide) (Vi polysaccharide)

Target
Vi polysaccharide
Molecular classification
Other
01

Overview

The Vi polysaccharide is a linear homopolymer of alpha-1,4-linked N-acetylgalactosaminuronic acid, variably O-acetylated at the C-3 position, which forms the outermost capsule of Salmonella enterica serovar Typhi (S. Typhi) [PMID: 28838621]. It serves as a critical virulence factor by masking surface antigens like the O-antigen from host recognition and protecting the bacterium from complement-mediated killing and phagocytosis by neutrophils [PMID: 24511111]. As a major surface-exposed molecule, it is the primary target for typhoid fever vaccines, including both plain polysaccharide and protein-conjugated formulations [WHO Position Paper, 2018]. While plain polysaccharide vaccines are effective in adults, conjugate vaccines (TCVs) link the Vi antigen to a carrier protein to elicit a T-cell dependent response, providing longer-lasting immunity and efficacy in infants [PMID: 30595437]. Targeting this polysaccharide is essential for preventing systemic infection and reducing the global burden of typhoid fever. The degree of O-acetylation is a key determinant of its immunogenicity, making it a focal point for quality control in vaccine manufacturing [PMID: 28838621].

Other names
Vi antigenVirulence antigenVi capsular polysaccharidePoly-alpha-1,4-GalNAcA
02

Mechanism of action

Active immunization to induce protective anti-Vi IgG antibodies that facilitate opsonophagocytosis and complement-mediated killing of Salmonella Typhi [PMID: 24511111].

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Poor immunogenicity in children under 2 years of age for unconjugated vaccinesPotential for immunological hyporesponsiveness with repeated doses of unconjugated polysaccharideInjection site reactions (pain, redness, swelling)Fever
06

Interacting drugs

Typhim Vi

4 more in the full profile.

07

Biomarkers

Anti-Vi IgG antibody titerAnti-Vi IgM antibody titer

Beyond the preview

Go deeper on Salmonella enterica serovar Typhi Vi capsular polysaccharide (Vi polysaccharide) (Vi polysaccharide).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salmonella enterica serovar Typhi Vi capsular polysaccharide (Vi polysaccharide) (Vi polysaccharide).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call